Page last updated: 2024-11-10

yangonin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

yangonin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281575
CHEMBL ID1098658
CHEBI ID10089
SCHEMBL ID1393965
MeSH IDM0286415

Synonyms (62)

Synonym
ccris 9372
r970u49v3c ,
unii-r970u49v3c
NSC212502 ,
nsc-212502
2h-pyran-2-one, 4-methoxy-6-(2-(4-methoxyphenyl)ethenyl)-, (e)-
5-hydroxy-3-methoxy-7-(p-methoxyphenyl)-2,4,6-heptatrienoic acid gamma-lactone
4-methoxy-6-(p-methoxystyryl)-2h-pyran-2-one
2h-pyran-2-one, 4-methoxy-6-(p-methoxystyryl)-
4-methoxy-6-(beta-(p-anisyl)vinyl)-alpha-pyrone
nsc 212502
nsc-112160
nsc112160
yangonin
NCGC00091909-01
UPCMLD-DP034:001
500-62-9
C09980
UPCMLD-DP034
UPCMLD-DP034:002
NCGC00091909-03
4-methoxy-6-[(e)-2-(4-methoxyphenyl)vinyl]-2h-pyran-2-one
4-methoxy-6-[2-(4-methoxyphenyl)ethenyl]pyran-2-one
CHEMBL1098658
chebi:10089 ,
4-methoxy-6-[(e)-2-(4-methoxyphenyl)ethenyl]pyran-2-one
dtxsid4034102 ,
cas-500-62-9
NCGC00260096-01
dtxcid2014102
tox21_202547
4-methoxy-6-[(e)-2-(4-methoxyphenyl)ethenyl]-2-pyranone
A827952
S9413
CCG-208617
AKOS022184639
yangonin [mi]
4-methoxy-6-((e)-2-(4-methoxyphenyl)ethenyl)pyran-2-one
2h-pyran-2-one, 4-methoxy-6-((1e)-2-(4-methoxyphenyl)ethenyl)-
SCHEMBL1393965
AC-34333
5-hydroxy-3-methoxy-7-(p-methoxyphenyl)-2,4,6-heptatrienoic acid .gamma.-lactone
4-methoxy-6-(.beta.-(p-anisyl)vinyl)-.alpha.-pyrone
XLHIYUYCSMZCCC-VMPITWQZSA-N
4-methoxy-6-[(e)-2-(4-methoxyphenyl)ethenyl]-2h-pyran-2-one #
2h-pyran-2-one, 4-methoxy-6-[2-(4-methoxyphenyl)ethenyl]-, (e)-
2h-pyran-2-one, 4-methoxy-6-[(1e)-2-(4-methoxyphenyl)ethenyl]-
HY-N0919
4-methoxy-6-[(e)-2-(4-methoxyphenyl)ethenyl]-2h-pyran-2-one
yangonin, analytical standard
sr-05000002174
SR-05000002174-2
4-methoxy-6-(4-methoxystyryl)-a-pyrone
4-methoxy-6-[2-(4-methoxyphenyl)ethenyl]-2h-pyran-2-one, 9ci
(e)-4-methoxy-6-(4-methoxystyryl)-2h-pyran-2-one
mfcd00221733
Q8048635
HMS3887I03
y100550
MS-23639
methoxyxerin
(e)-4-methoxy-6-[2-(4-methoxyphenyl)ethenyl]pyran-2-one

Research Excerpts

Actions

ExcerptReferenceRelevance
"Yangonin was found to activate FXR to exert hepatoprotective effect against cholestatic liver injury."( Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Fu, T; Gao, X; Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Ning, C; Sun, H; Wang, C; Yang, X; Zou, M, 2018
)
2.64

Treatment

Yangonin treatment remarkably ameliorated TAA-induced liver injury by reducing relative liver weight, as well as serum ALT and AST activities. Yangonin is also effective in treating estrogen-induced cholestasis through increasing bile flow and biliary bile acid output.

ExcerptReferenceRelevance
"Yangonin treatment remarkably ameliorated TAA-induced liver injury by reducing relative liver weight, as well as serum ALT and AST activities."( Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation.
Fu, T; Liu, K; Ma, X; Meng, Q; Sun, H; Sun, P; Wang, C; Wang, J; Wang, X; Wu, J, 2019
)
1.56
"Yangonin treatment ameliorates estrogen-induced cholestasis through increasing bile flow and biliary bile acid output."( Yangonin protects against estrogen-induced cholestasis in a farnesoid X receptor-dependent manner.
Dong, R; Gao, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Sun, H; Wang, C; Wang, J; Wu, J, 2019
)
2.68

Toxicity

ExcerptReferenceRelevance
" Thus, in vitro kava does not appear to be activated to toxic metabolites by enzymes known to be important in metabolic toxicity."( Kava does not display metabolic toxicity in a homogeneous cellular assay.
Dike, LE; Harkey, MR; Henderson, GL; Zou, L, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
"To examine the bioavailability of kavalactones in vitro and the possible differences in their bioavailability because of variations in either chemical structure or the method of extraction used."( Permeability studies of Kavalactones using a Caco-2 cell monolayer model.
Blanchfield, JT; Bone, KM; Lehmann, RP; Matthias, A; Penman, KG; Toth, I, 2007
)
0.34
"Caco-2 cell monolayers were used to determine the potential bioavailability of kavalactones."( Permeability studies of Kavalactones using a Caco-2 cell monolayer model.
Blanchfield, JT; Bone, KM; Lehmann, RP; Matthias, A; Penman, KG; Toth, I, 2007
)
0.34
" Not all differences in their bioavailability can be related to kavalactone structural differences as it appears that bioavailability may also be affected by co-extracted compounds."( Permeability studies of Kavalactones using a Caco-2 cell monolayer model.
Blanchfield, JT; Bone, KM; Lehmann, RP; Matthias, A; Penman, KG; Toth, I, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
2-pyranonesA pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.12200.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
LuciferasePhotinus pyralis (common eastern firefly)Potency5.14550.007215.758889.3584AID1224835
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
pregnane X receptorRattus norvegicus (Norway rat)Potency50.11870.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.99160.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency4.31720.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency11.22020.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency9.95640.000221.22318,912.5098AID1259247; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.78050.001022.650876.6163AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.00280.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency2.57520.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency39.81070.000817.505159.3239AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency7.34940.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency22.38720.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency22.15950.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.40050.000229.305416,493.5996AID1259244; AID1259248; AID743079; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.66840.001019.414170.9645AID588537
aryl hydrocarbon receptorHomo sapiens (human)Potency3.89790.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.40070.001723.839378.1014AID743083
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID902
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
histone deacetylase 9 isoform 3Homo sapiens (human)Potency6.37890.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency1.46720.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
caspase-1 isoform alpha precursorHomo sapiens (human)Potency39.81070.000311.448431.6228AID900
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency2.79470.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency2.79470.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency1.88340.026622.448266.8242AID651802
Caspase-7Homo sapiens (human)Potency31.62283.981118.585631.6228AID889
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency20.99200.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency22.19910.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1090312Antifungal activity against Fusarium solani assessed as growth inhibition at 10 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090310Antifungal activity against Fusarium oxysporum assessed as growth inhibition at 10 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1450314Cytotoxicity against mouse MC3T3-E1 cells assessed as cell number at 30 uM measured after 4 days by WST-8 assay relative to control2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Synthesis of novel 5,6-dehydrokawain analogs as osteogenic inducers and their action mechanisms.
AID1090313Antifungal activity against Colletotrichum gloeosporioides assessed as growth inhibition at 50 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID666150Inhibition of PA endonuclease at 10 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID1090314Antifungal activity against Colletotrichum gloeosporioides assessed as growth inhibition at 10 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090317Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as inhibition of shoot length at 10 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090299Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as inhibition of germination at 10 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090300Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as inhibition of germination at 1 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090306Herbicidal activity against Lactuca sativa cv. Great Lakes 366 (lettuce) assessed as inhibition of germination at 1 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1090316Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as inhibition of root length at 1 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID481211Induction of HO-1 protein expression in rat PC12 cells at 10 uM after 24 hrs by Western blot analysis2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
A novel kavalactone derivative protects against H2O2-induced PC12 cell death via Nrf2/ARE activation.
AID1450309Osteogenic activity in mouse MC3T3-E1 cells assessed as increase in ALP activity at 30 uM measured after 4 days relative to control2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Synthesis of novel 5,6-dehydrokawain analogs as osteogenic inducers and their action mechanisms.
AID666151Inhibition of PA endonuclease at 1 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1090315Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as inhibition of root length at 10 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090304Herbicidal activity against Lactuca sativa cv. Great Lakes 366 (lettuce) assessed as inhibition of shoot length at 1 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090307Antifungal activity against Hypocrea rufa assessed as growth inhibition at 10 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090305Herbicidal activity against Lactuca sativa cv. Great Lakes 366 (lettuce) assessed as inhibition of germination at 10 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090311Antifungal activity against Fusarium solani assessed as growth inhibition at 50 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090308Antifungal activity against Hypocrea rufa assessed as growth inhibition at 50 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090298Herbicidal activity against Echinochloa crus-galli (barnyard grass) assessed as inhibition of shoot length at 1 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090303Herbicidal activity against Lactuca sativa cv. Great Lakes 366 (lettuce) assessed as inhibition of shoot length at 10 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090309Antifungal activity against Fusarium oxysporum assessed as growth inhibition at 50 ppm after 4 days relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1090302Herbicidal activity against Lactuca sativa cv. Great Lakes 366 (lettuce) assessed as inhibition of root length at 1 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
AID1450310Osteogenic activity in mouse MC3T3-E1 cells assessed as increase in mineralization at 30 uM measured after 10 days by alizarin red S staining based assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Synthesis of novel 5,6-dehydrokawain analogs as osteogenic inducers and their action mechanisms.
AID481210Activation of Nrf2 in rat PC12 cells at 10 uM after 24 hrs by antioxidant response element-driven luciferase reporter gene assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
A novel kavalactone derivative protects against H2O2-induced PC12 cell death via Nrf2/ARE activation.
AID1090301Herbicidal activity against Lactuca sativa cv. Great Lakes 366 (lettuce) assessed as inhibition of root length at 10 ppm relative to untreated control2006Journal of agricultural and food chemistry, Feb-08, Volume: 54, Issue:3
Herbicidal and Fungicidal Activities of Lactones in Kava (Piper methysticum).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.33)18.2507
2000's9 (30.00)29.6817
2010's16 (53.33)24.3611
2020's4 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.35 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.52 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.03%)4.05%
Observational0 (0.00%)0.25%
Other32 (96.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]